Shots:
- Glenmark has launched Remogliflozin (SGLT2 inhibitors, 100mg, ) + Vildagliptin (DPP4 inhibitors, 50mg,) + Metformin (500/1000mg) as FDC for the management of T2D in India. The FDC will be marketed under two brand names; Remo MV & Remozen MV
- Glenmark’s FDC will improve patient compliance and provide glycemic & extra glycemic benefits to patients with uncontrolled T2D at an affordable cost in India
- The company has received DCGI’s approval for the manufacturing and marketing of the FDC in late Sep’21. Glenmark has become the first company to launch Remogliflozin (100mg) + Vildagliptin (50mg) globally as a fixed-dose combination in 2020
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post Glenmark launches Remogliflozin + Vildagliptin + Metformin as Fixed Dose Combination for the Treatment of Type 2 Diabetes in India first appeared on PharmaShots.
